The global viral vector manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2%. This market is consolidated in nature with a few global players. In 2017, Lonza (Switzerland), Merck (Germany), and Oxford BioMedica (UK), were the top three players in the viral vector manufacturing market.
Lonza Group(Switzerland) is a global life sciences company that provides integrated solutions and products to various markets, including pharmaceuticals, biotech, nutrition, and personal care. Lonza’s core capabilities lie in the areas of research, development, manufacturing, and commercialization. It offers a wide range of services and products, including active pharmaceutical ingredients (APIs), drug delivery technologies, cell and gene therapies, microbial control solutions, and specialty chemicals. The company operates through four key business segments namely, Biologics, Small Molecules, Cell & Gene and Capsule & Health Ingredients. The company offers viral vector and plasmid DNA manufacturing products and services through its biologics and cell & gene therapy segment.
The company focuses on organic and inorganic growth strategies such as product launch, collaborations, and partnerships to strengthen its presence in the viral vector and plasmid DNA manufacturing market. The company has launched in recent years, such as TheraPEAK SfAAV Medium, an a first chemically defined, non-animal origin medium designed specifically to produce Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications. The company focuses on improving its R&D capabilities to unlock additional synergies and growth opportunities.
Merck KGaA(Germany) is a healthcare and life science company that develops, manufactures, and markets pharmaceutical and biopharmaceutical products, specialty chemicals, high-tech materials, and life science research and diagnostic tools. The company operates through three business segments- Healthcare, Life Science, and Electronics. The Life Science segment is further segmented into Process Solutions, Science & Lab Solutions, and Life Science Services. The company operates in the viral vector and plasmid DNA manufacturing market through the Process Solutions division of life science segment.
The company provides process development and optimization services to help biopharmaceutical companies in their viral vector and plasmid DNA manufacturing endeavors. These services include process scale-up, optimization, and characterization, with the aim of improving efficiency, yield, and quality. By leveraging its expertise and offerings in cell culture, molecular biology, and process development, Merck KGaA can support biopharmaceutical companies throughout various stages of viral vector and plasmid DNA manufacturing processes.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=89341986
Thermo Fisher Scientific Inc. (US) is one of the leading players in the life science industry, with a strong market presence in more than 80 countries. The company is involved in the development, manufacturing, sales, and distribution of analytical instruments, equipment, reagents and consumables, software, and services. The company operates its business through four key segments—Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics. The company offers viral vector and plasmid DNA manufacturing products and services through the Life Sciences Solutions business.
Oxford BioMedica (UK) was the third player in the viral vector manufacturing market in 2017. The company owns a broad and robust viral vector therapy pipeline allowing the company to collaborate with leading pharma and biopharma companies such as Novartis and Bioverativ (US). The company is a pioneer in developing lentiviral vector therapy using its proprietary LentiVector Platform. It also benefits from the out-licensing of this platform. Biomedica focuses on seeking opportunities in important markets such as South Korea, Switzerland, and Italy.
Some other important players in the global viral vector manufacturing market include CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), Spark Therapeutics (US), REGENXBIO (US), FinVector (Finland), Novasep (France), Kaneka Eurogentec (Japan), and MassBiologics (US). These companies also have well-established viral vector manufacturing capabilities and are focused on expanding their market reach through collaborations with cell and gene therapy companies.
